Our study has several limitations: i) larger sample size is needed to explore the clinical characteristics of circTP63 in prostate cancer; ii) lack of clinical information to verify the association of circTP63 and disease prognosis; iii) although VAPA was proven to promote prostate cancer progression in our study, more attention should be focused on exploring the specific mechanism by which VAPA promotes prostate cancer progression. This evidence concerns the gene VAPA and prostate carcinoma.